However, while intestinal FXR antagonism by Gly-β-MCA was shown to be beneficial in improving metabolic health in obesity, it may be an undesirable effect of cholestasis treatment given the protective role of FXR against intracellular bile acid accumulation (9). This evidence concerns the gene NR1H4 and obesity disorder.